Multiple targeting by the antitumor drug tamoxifen: a structure-activity study. - Archive ouverte HAL Access content directly
Journal Articles Current Medicinal Chemistry Anticancer Agents Year : 2004

Multiple targeting by the antitumor drug tamoxifen: a structure-activity study.

(1) , (1) , (1)
1

Abstract

Tamoxifen is a well-known antiestrogen used for the hormonotherapy of estrogen receptor positive breast cancer. In addition to its high affinity binding to the estrogen receptor (ER), tamoxifen binds with comparable affinity to the microsomal antiestrogen binding site (AEBS), and inhibits with a micromolar efficiency, protein kinase C (PKC), calmodulin (CaM)-dependent enzymes and Acyl CoenzymeA: Cholesterol Acyl Transferase (ACAT). Each of these tamoxifen targets might explain the genomic as well as non-genomic effects of tamoxifen. In this review, we will report current knowledge about the structural features of tamoxifen involved in this multiple targeting. These data provide a useful guide for the conception of selective ligands of ERs, AEBS, PKC, CaM or ACAT based on the chemical structure of tamoxifen.
Not file

Dates and versions

inserm-00090772 , version 1 (02-09-2006)

Identifiers

  • HAL Id : inserm-00090772 , version 1
  • PUBMED : 15579015

Cite

Philippe de Médina, Gilles Favre, Marc E. Poirot. Multiple targeting by the antitumor drug tamoxifen: a structure-activity study.. Current Medicinal Chemistry Anticancer Agents, 2004, 4, pp.491-508. ⟨inserm-00090772⟩
63 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More